Skip to content
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Rheumatology

The Science of Diagnosis: Biology and Imaging

At a Glance

Takayasu arteritis is diagnosed by combining symptoms, blood-test trends, and pictures of the blood vessels rather than one definitive test. Doctors interpret MRA, PET-CT, CT angiography, or ultrasound alongside the clinical picture to separate active inflammation from healing or other diseases.

Diagnosing Takayasu Arteritis is a meticulous process that combines the latest in medical imaging with a deep understanding of how your immune system interacts with your circulatory system. Because the symptoms can be vague, doctors must look closely to see the biological changes occurring within your artery walls.

The Biological Mechanism: An Internal Conflict

Takayasu Arteritis is driven by granulomatous inflammation—a specific type of long-term immune response where your body’s defense cells clump together in the walls of your largest blood vessels [1][2]. While the precise initiating cause is still being studied, the mechanics of the inflammation are well documented.

This process involves several key players in your immune system:

  • T Cells and Macrophages: These white blood cells mistakenly enter the vessel wall, starting at the tiny blood vessels that feed the artery itself (the vasa vasorum) [1]. They release chemical signals that cause the wall to swell and eventually scar [3].
  • Interleukin-6 (IL-6): This is a major “alarm” protein in your body. High levels of IL-6 drive much of the systemic “flu-like” feeling, such as fever and fatigue [4][5].
  • Vessel Remodeling: As the inflammation continues, the vessel wall may thicken (intimal proliferation), which narrows the space for blood to flow (stenosis). Conversely, if the structural proteins (like elastin) are destroyed, the vessel may weaken and bulge into an aneurysm [6][7].

The Diagnostic Pathway

There is no single blood test that can “prove” you have Takayasu Arteritis. Instead, your medical team uses a combination of clinical judgment and specialized criteria.

Clinical Diagnosis vs. Classification Criteria

In 2022, the American College of Rheumatology (ACR) and EULAR released updated classification criteria [8][9]. It is important to understand that these criteria are primarily designed for research—to ensure that patients in clinical trials have the same condition.

For a “classic” case, the criteria require you to be 60 years old or younger and have imaging proof of large-vessel vasculitis. Points are then added for findings like being female (+1), having limb claudication (+2), or having a large blood pressure difference between arms (+1) [8][9].

Crucially, a clinical diagnosis is different. Your doctor may diagnose you with Takayasu Arteritis even if you do not meet every single research criterion, provided your symptoms and imaging are consistent with the disease and other mimics have been ruled out [10][11].

The Role of Imaging

Imaging is the cornerstone of both diagnosis and long-term monitoring. Because doctors cannot easily biopsy your aorta, they rely on high-tech “pictures” to see what is happening. However, no scan alone establishes active disease or justifies escalating immunosuppression; imaging must be combined with your clinical symptoms and lab trends, as thickening or metabolic uptake can sometimes reflect healing or remodeling rather than active inflammation [12][13].

  • MRI and MRA (Magnetic Resonance Angiography): This is often recommended as a first choice for assessing large vessel vasculitis by major guidelines [12][14]. It provides detailed images of the vessel walls without using ionizing radiation, though it may require gadolinium contrast. It can show swelling or edema in the wall, though these findings must be interpreted carefully [15][16].
  • PET-CT: This scan uses a radioactive tracer to detect high metabolic activity. It is excellent at detecting inflammation that might not be visible on other scans, but the FDG tracer uptake is not perfectly specific and can persist during healing or remodeling, and the scan involves radiation exposure [15][17].
  • CTA (CT Angiography): This provides a very sharp map of your blood vessels and is excellent for planning surgeries or seeing detailed structural changes like calcifications. However, it involves ionizing radiation and requires iodinated contrast, which must be carefully considered for patients with kidney problems [15][18].
  • Ultrasound: A quick, non-invasive way to look at accessible vessels like the carotid arteries in the neck. While it cannot see deep into the chest, it is a helpful tool for routine check-ups [15][19].

Ruling Out the Mimics

Because several conditions can look like Takayasu Arteritis on a scan, your doctor must play detective to rule out other possibilities:

  • Giant Cell Arteritis (GCA): This is very similar but typically affects people over age 50 and often involves the temporal arteries in the scalp [20][21].
  • Atherosclerosis: This is the “hardening of the arteries” common with aging or high cholesterol. Unlike vasculitis, it usually doesn’t cause uniform, concentric wall thickening [22][16].
  • Fibromuscular Dysplasia (FMD): A non-inflammatory condition where the vessel walls grow abnormally, often creating a “string of beads” appearance on imaging [22].
  • Infections: Certain infections, like tuberculosis or syphilis, can cause inflammation of the aorta (aortitis) and must be ruled out before starting immune-suppressing treatments [22][23].

By combining your personal history with these advanced tools, your care team can confirm the diagnosis and, more importantly, track whether your treatment is successfully quieting the inflammation.

Common questions in this guide

How is Takayasu arteritis diagnosed when there is no single confirming test?
Doctors combine your symptoms, medical history, examination findings, blood-test trends, and vascular imaging. They also rule out conditions that can look similar, such as giant cell arteritis, atherosclerosis, fibromuscular dysplasia, and certain infections. The 2022 ACR/EULAR criteria help standardize research groups but do not replace a clinician’s judgment.
Which scan is usually used to look for Takayasu arteritis?
Magnetic resonance angiography, or MRA, is often recommended first for large-vessel vasculitis because it shows the vessel wall without ionizing radiation. PET-CT, CT angiography, and ultrasound may be chosen for different questions, such as detecting metabolic activity, mapping structural changes, or checking accessible arteries.
Can a scan show whether my Takayasu arteritis is active?
Not by itself. Vessel-wall thickening or tracer uptake can sometimes persist during healing or remodeling, so doctors interpret imaging with your symptoms and blood-test trends before deciding whether inflammation is active or treatment should change.
What do ESR and CRP tell doctors about Takayasu arteritis?
ESR and CRP are blood tests that can be followed as part of the overall assessment of inflammation. Your doctor interprets their trends together with symptoms and imaging, because no single result can establish active Takayasu arteritis on its own.
How do doctors tell Takayasu arteritis apart from similar conditions?
They compare your age, symptoms, medical history, examination, and imaging pattern. Giant cell arteritis more often affects people over 50 and may involve the temporal arteries, atherosclerosis usually causes different wall changes, fibromuscular dysplasia can create a string-of-beads pattern, and infections can cause aortitis.
What should I know about the risks and uses of different scans?
MRA avoids ionizing radiation but may require gadolinium contrast. PET-CT uses radiation and its tracer uptake is not specific, while CT angiography uses radiation and iodinated contrast that may need special consideration with kidney problems; ultrasound is noninvasive but cannot see deep chest vessels.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific imaging findings suggest that my disease is currently 'active' versus showing signs of past damage or remodeling?
  2. 2.Since I am being treated, how should we interpret my ESR and CRP levels in combination with my symptoms?
  3. 3.Why is this specific imaging modality (e.g., MRA or CTA) the preferred choice for my current situation?
  4. 4.Based on my imaging, are there specific arterial territories (like the renal or carotid arteries) that need extra monitoring?
  5. 5.How do you distinguish my symptoms from other conditions like giant cell arteritis or atherosclerosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Common Autoantibody among Takayasu Arteritis and Ulcerative Colitis: A Possible Pathophysiology That Includes Gut-Vessel Connection in Vascular Inflammation.

    Shirai T

    JMA journal 2023; (6(3)):265-273 doi:10.31662/jmaj.2023-0038.

    PMID: 37560375
  2. 2

    Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences.

    Watanabe R, Berry GJ, Liang DH, et al.

    Current rheumatology reports 2020; (22(10)):68 doi:10.1007/s11926-020-00948-x.

    PMID: 32845392
  3. 3

    Augmented PFKFB3-mediated glycolysis by interferon-γ promotes inflammatory M1 polarization through the JAK2/STAT1 pathway in local vascular inflammation in Takayasu arteritis.

    Chen R, Wang J, Dai X, et al.

    Arthritis research & therapy 2022; (24(1)):266 doi:10.1186/s13075-022-02960-1.

    PMID: 36510278
  4. 4

    Th1 and Th17 cytokines drive inflammation in Takayasu arteritis.

    Saadoun D, Garrido M, Comarmond C, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2015; (67(5)):1353-60 doi:10.1002/art.39037.

    PMID: 25604824
  5. 5

    Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease.

    Singh K, Rathore U, Rai MK, et al.

    Journal of inflammation research 2022; (15()):1521-1541 doi:10.2147/JIR.S355881.

    PMID: 35256852
  6. 6

    Takayasu Arteritis.

    Russo RAG, Katsicas MM

    Frontiers in pediatrics 2018; (6()):265 doi:10.3389/fped.2018.00265.

    PMID: 30338248
  7. 7

    The role of CD34-high endothelial cells and FGF2 in vasa vasorum angiogenesis of Takayasu arteritis.

    Li T, Wang C, Zhu J, et al.

    Clinical rheumatology 2026; (45(6)):3621-3633 doi:10.1007/s10067-026-08140-9.

    PMID: 42067750
  8. 8

    2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis.

    Grayson PC, Ponte C, Suppiah R, et al.

    Annals of the rheumatic diseases 2022; (81(12)):1654-1660 doi:10.1136/ard-2022-223482.

    PMID: 36351705
  9. 9

    2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis.

    Grayson PC, Ponte C, Suppiah R, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(12)):1872-1880 doi:10.1002/art.42324.

    PMID: 36349501
  10. 10

    Classification of large vessel vasculitis: Can we separate giant cell arteritis from Takayasu arteritis?

    Koster MJ, Warrington KJ

    Presse medicale (Paris, France : 1983) 2017; (46(7-8 Pt 2)):e205-e213 doi:10.1016/j.lpm.2016.11.032.

    PMID: 28774474
  11. 11

    Validation of the 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis.

    Tomelleri A, Padoan R, Kavadichanda CG, et al.

    Rheumatology (Oxford, England) 2023; (62(10)):3427-3432 doi:10.1093/rheumatology/kead161.

    PMID: 37018125
  12. 12

    EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update.

    Dejaco C, Ramiro S, Bond M, et al.

    Annals of the rheumatic diseases 2024; (83(6)):741-751 doi:10.1136/ard-2023-224543.

    PMID: 37550004
  13. 13

    The Role of Imaging in Monitoring Large Vessel Vasculitis: A Comprehensive Review.

    Sopa I, Pereira da Costa R, Martins Martinho J, Ponte C

    Biomolecules 2025; (15(11)) doi:10.3390/biom15111505.

    PMID: 41301423
  14. 14

    EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice.

    Dejaco C, Ramiro S, Duftner C, et al.

    Annals of the rheumatic diseases 2018; (77(5)):636-643 doi:10.1136/annrheumdis-2017-212649.

    PMID: 29358285
  15. 15

    Imaging modalities for the diagnosis and disease activity assessment of Takayasu's arteritis: A systematic review and meta-analysis.

    Barra L, Kanji T, Malette J, et al.

    Autoimmunity reviews 2018; (17(2)):175-187 doi:10.1016/j.autrev.2017.11.021.

    PMID: 29313811
  16. 16

    Diagnostic Approaches for Large Vessel Vasculitides.

    Betrains A, Blockmans D

    Open access rheumatology : research and reviews 2021; (13()):153-165 doi:10.2147/OARRR.S282605.

    PMID: 34113183
  17. 17

    Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis.

    van der Geest KSM, Treglia G, Glaudemans AWJM, et al.

    European journal of nuclear medicine and molecular imaging 2021; (48(12)):3886-3902 doi:10.1007/s00259-021-05362-8.

    PMID: 33942141
  18. 18

    Comparative study of 18F-FDG PET/CT and CT angiography in detection of large vessel vasculitis.

    Moragas Solanes M, Andreu Magarolas M, Martín Miramon JC, et al.

    Revista espanola de medicina nuclear e imagen molecular 2019; (38(5)):280-289 doi:10.1016/j.remn.2019.03.002.

    PMID: 31126839
  19. 19

    Contrast-enhanced Ultrasonography for Monitoring Arterial Inflammation in Takayasu Arteritis.

    Li Z, Zheng Z, Ding J, et al.

    The Journal of rheumatology 2019; (46(6)):616-622 doi:10.3899/jrheum.180701.

    PMID: 30824642
  20. 20

    Large-Vessel Vasculitis in Ophthalmology: Giant Cell Arteritis and Takayasu Arteritis.

    Dhanani U, Zhao MY, Charoenkijkajorn C, et al.

    Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2022; (11(2)):177-183 doi:10.1097/APO.0000000000000514.

    PMID: 35533336
  21. 21

    [Large vessel vasculitis : Giant cell arteritis and Takayasu arteritis].

    Villiger PM

    Zeitschrift fur Rheumatologie 2017; (76(6)):509-523 doi:10.1007/s00393-017-0331-3.

    PMID: 28638968
  22. 22

    Diagnosis and differential diagnosis of large-vessel vasculitides.

    Keser G, Aksu K

    Rheumatology international 2019; (39(2)):169-185 doi:10.1007/s00296-018-4157-3.

    PMID: 30221327
  23. 23

    Mimickers of Large Vessel Giant Cell Arteritis.

    Ramon A, Greigert H, Ornetti P, et al.

    Journal of clinical medicine 2022; (11(3)) doi:10.3390/jcm11030495.

    PMID: 35159949

This page explains Takayasu arteritis diagnosis for informational purposes only and does not constitute medical advice. Your healthcare team should interpret your imaging and blood tests in the context of your symptoms.

Get notified when new evidence is published on Takayasu arteritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.